An Exciting Journey
Molecular, Cellular and Clinical Allergology (MCCA) PhD Symposium and SFB F46 'Towards prevention and therapy of allergy' Closing Event on Mechanisms of IgE-associated Diseases and Novel Approaches for the Therapy of Allergy and Beyond
Molecular, Cellular and Clinical Allergology (MCCA) is a doctoral program of the Medical University of Vienna and the Veterinary University of Vienna, Austria.
SFB F46 'Towards prevention and therapy of allergy' is a special research program located at the Medical University of Vienna and the Karl-Franzens-University of Graz, Austria.
Both programs are funded by the FWF Austrian Science Fund.
Programm
08:30 - 09:00 Registration
09:00 - 09:15 Opening
- Michaela Fritz, Vice Rector for Research and Innovation, Medical University of Vienna
- Winfried Pickl, MCCA Speaker
- Rudolf Valenta, SFB Speaker
09:15 - 10:10 Session One
- Mohamed Ridha Barbouche, Institut Pasteur de Tunis, Tunisia: Molecular dissection of and IgE specificities behind hyper-IgE syndromes
- Sonja Kopanja, Medical University of Vienna: Soluble FceRI disrupts cell-bound chimeric IgE
10:10 - 11:05 Session Two
- Ted Jardetzky, Stanford University, California, USA: On the contribution of IgE-receptors to the pathology of allergy
- Sergio Villazala, Medical University of Vienna: The crosslinking ability of IgE-allergen complexes and the concentrations of specific IgE determine the extent of T cell activation mediated by CD23-FAP
11:05 - 11:30 Coffee Break
11:30 - 12:25 Session Three
- Alain Jacquet, Chulalongkorn University, Bangkok, Thailand: How house dust mite allergens target the adaptive and innate immune system
- Tanja Kalic, Medical University of Vienna: The role of tropomyosin in cross-reactivity between house dust mite and shellfish
12:25 - 14:45 Lunch Break and Guided Poster Session
14:45 - 15:40 Session Four
- Christopher Paige, Princess Margaret Cancer Centre, Toronto, Canada: Interleukin-12 based modulation of (tumor-)immunity
- Natalia Alkon, Medical University of Vienna: Innate lymphoid cells (ILCs) in skin and blood
15:40 - 16:05 Coffee Break
16:05 - 17:00 Session Five
- Torsten Tonn, Medical Faculty Carl Gustav Carus, TU Dresden, Germany: In vivo eradication of malignant and non-malignant (autoreactive, allergen-specific) cell types by CAR technology
- Peter Tauber, Medical University of Vienna: The kinase inhibitor BX-795 is a TCR signaling modulator that stimulates IL-2 while attenuating Th2 responses
17:00 Closing Remarks